Skip to Content

We invite you to try out our new beta eCFR site at https://ecfr.federalregister.gov. We’ve made big changes to make the eCFR easier to use. Be sure to leave feedback using the 'Help' button on the bottom right of each page!

Notice

March 10 Through April 30, 2020, Public Meetings; Postponement, Cancellation, or Remote Only

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration is announcing that certain meetings involving the Center for Drug Evaluation and Research (CDER) from March 10 through April 30, 2020, are postponed, cancelled, or modified to take place remotely.

DATES:

For dates that have been either postponed or cancelled, see table 1 in the SUPPLEMENTARY INFORMATION section.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Kim Thomas, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6282, Silver Spring, MD 20993-0002, 301-796-2357, Kimberly.K.Thomas@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Certain public meetings involving CDER from March 10 through April 30, 2020, are postponed, cancelled, or modified to take place remotely due to extenuating circumstances. The meetings that are postponed or canceled as part of this notice are listed in table 1. If a meeting is rescheduled, information about the rescheduled meeting will be provided in the future. The meeting that will no longer take place in person and instead take place by webcast only as part of this notice is listed in table 2.[1]

Start Printed Page 15790

Table 1—CDER Meetings Postponed or Cancelled

Meeting typeMeeting titleOriginal meeting dateDocket No.Federal Register citation
Public MeetingPatient-Focused Drug Development for Stimulant Use DisorderMar. 10, 2020FDA-2020-N-025985 FR 8877, Feb. 18, 2020.
Public MeetingPatient-Focused Drug Development for VitiligoMar. 30, 2020FDA-2020-N-025585 FR 8004, Feb. 12, 2020.
Public MeetingScientific and Ethical Considerations for the Inclusion of Pregnant Women in Clinical TrialsApr. 16, 2020FDA-2020-N-000185 FR 14207, Mar. 11, 2020.
Public MeetingPrescription Drug User Fee Act of 2017; Electronic Submissions and Data StandardsApr. 22, 2020FDA-2018-N-433785 FR 6547, Feb. 5, 2020.

Table 2—CDER Meeting Held Remotely

Meeting typeMeeting titleOriginal meeting dateDocket No.Federal Register citationRemote information
Public MeetingUnited States Food and Drug Administration and Health Canada Joint Regional Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human UseApr. 3, 2020FDA-2020-N-025685 FR 13659, Mar. 9, 2020https://www.fda.gov/​drugs/​news-events-human-drugs/​health-canada-and-fda-joint-public-consultation-international-council-harmonisation-technical-0.
Start Signature

Dated: March 16, 2020.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.

End Signature End Supplemental Information

Footnotes

1.  Up-to-date information about public meetings involving CDER is available on the internet at https://www.fda.gov/​drugs/​news-events-human-drugs/​meetings-conferences-workshops-drugs.

Back to Citation

[FR Doc. 2020-05743 Filed 3-18-20; 8:45 am]

BILLING CODE 4164-01-P